BioAtla to Report Q2 2024 Financial Results and Business Highlights on August 8, 2024

BioAtla, Inc. (Nasdaq: BCAB), a leading clinical-stage biotechnology firm, announced plans for a conference call and webcast on August 8, 2024, to discuss its financial performance for the second quarter of 2024. The session is scheduled for 4:30 p.m. ET, and attendees can join via a dedicated webcast link or dial into the call using the provided domestic and international numbers. The conference ID for the call is "BIOATLA."

The company's second-quarter financial results will be available on BioAtla's website under the "News Releases" section before the call. A replay of the discussion will be accessible later through the "Events & Presentations" area in the Investors section of their site.

BioAtla is a globally recognized clinical-stage biotechnology firm with operations in San Diego, California, and Beijing, China. The company collaborates with BioDuro-Sundia, a provider specializing in preclinical development services. BioAtla's innovative work focuses on developing Conditionally Active Biologics (CAB) technology, which includes reversible monoclonal and bispecific antibodies and other protein therapeutic candidates. CAB products aim to provide selective targeting and enhanced efficacy while minimizing toxicity and reducing manufacturing costs compared to traditional antibodies.

The company holds extensive patent coverage for its CAB technology and products, with over 765 active patent matters, including more than 500 issued patents. These patents cover various methods related to the production, screening, and manufacturing of CAB products and composition of matter coverage for specific items in all major markets worldwide.

BioAtla's portfolio includes two pioneering CAB programs currently in Phase 2 clinical trials: mecbotamab vedotin, an AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Additionally, the company is developing evalstotug, a novel CTLA-4 inhibitor in Phase 2 testing, designed to minimize systemic toxicity and enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibodies.

The company is also advancing its first dual CAB bispecific T-cell engager antibody, BA3182, which targets EpCAM, a protein highly expressed in many adenocarcinomas, while engaging CD3-expressing T cells. This program is currently in Phase 1 development.

Moreover, BioAtla has received FDA clearance for an Investigational New Drug (IND) application for its next-generation CAB-Nectin4-ADC, BA3361. This product represents the company's first glycoconjugate.

BioAtla's innovative approaches and proprietary technologies position it as a leader in the development of next-generation antibody therapeutics aimed at treating solid tumors effectively and safely.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!